 |
Botox® (Botulinum Toxin Type A) was approved for medical use by the FDA in December 1989. Since then, it has become the treatment of choice for a number of movement disorders. These include such conditions as
cervical dystonia, blepharospasm, hemifacial spasm and
limb dystonia. All of these conditions are characterized by involuntary muscle contraction and twitching. Botox® helps to relieve symptoms by decreasing the treated muscles’ ability to contract. Other newer uses for Botox® have been tried over the past few years. |
|
 |
|
